Breaking News Instant updates and real-time market news.

NVS

Novartis

$78.29

-0.16 (-0.20%)

17:07
10/09/16
10/09
17:07
10/09/16
17:07

Novartis reports data from ASCEND-3, ASCEND-5 trials of Zykadia

Novartis announced updated results from the Phase II ASCEND-3 trial, which demonstrated that anaplastic lymphoma kinase-positive non-small cell lung cancer patients taking Zykadia as their first ALK inhibitor had a median progression-free survival of 18.4 months, with a median follow-up time of 25.9 months. Further, in a sub-analysis of these data, patients who entered the study with brain metastases at baseline experienced an overall response rate of 63.3% and a disease control rate of 83.7%. These results were similar to those in patients without brain metastases, who demonstrated an ORR of 64.0% and DCR of 88.0%. At the time of analysis, the estimated 18-month overall survival rate was 73.4%. This population also demonstrated an ORR of 63.7% and median duration of response of 23.9 months. A decrease in tumor burden from baseline was shown in 94.7% patients. Results from the Phase III ASCEND-5 study were also presented for the first time. The ASCEND-5 study assessed median PFS in patients previously treated with crizotinib and one or two prior regimens of cytotoxic chemotherapy who then received either Zykadia or standard chemotherapy. Results demonstrated a statistically significant and clinically meaningful improvement in median PFS by BIRC for patients taking Zykadia versus chemotherapy. Median PFS by BIRC for Zykadia and chemotherapy were 5.4 months vs. 1.6 months, respectively.

NVS Novartis
$78.29

-0.16 (-0.20%)

08/31/16
LEER
08/31/16
NO CHANGE
Target $61
LEER
Outperform
Teva price target lowered to $61 from $66 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva (TEVA) to $61 from $66 on loss of Copaxone patent challenge as an upside catalyst. The analyst believes Teva's share price implies a generic entrant sometime in the second half of 2017 after losing an Inter Partes Review decision on two Copaxone 40mg anchor patents. In order to mitigate EPS downside in 2017-2018 and eliminate business uncertainty, Gerberry thinks the company should settle its Copaxone patent dispute with Novartis (NVS) and Momenta (MNTA), which he sees as "the most credible" generic threat. The analyst reiterates an Outperform rating on Teva's shares.
08/31/16
PIPR
08/31/16
NO CHANGE
PIPR
Piper's Schimmer unsure of impact from Novartis CAR-T shakeup
Piper Jaffray analyst Joshua Schimmer said he's struggling with the implications of the news that Novartis (NVS) is reportedly eliminating its Cell and Gene Therapy unit as a stand-alone entity, which is primarily focused on development of CAR-T and adoptive immunotherapies. On the one hand, removing a leading competitor is a positive for the rest of the field, Schimmer tells investors in a research note. On the other hand, the move by Novartis could signal "significant challenges" in the field, the analyst adds. Schimmer continues to prefer companies "with unique and differentiated approaches," namely Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), Amgen (AMGN), Celgene (CELG) and bluebird bio (BLUE). Juno Therapeutics (JUNO) and Kite Pharma (KITE) are down 6% and 5%, respectively, in midday trading.
09/02/16
LEER
09/02/16
NO CHANGE
LEER
Outperform
Teva third Copaxone patent invalidated as expected, says Leerink
Leerink analyst Jason Gerberry says Teva (TEVA) suffered a largely expected loss in its Copaxone 40mg patent battle, with the Patent Trial and Appeal Board, or PTAB, ruling a third patent invalid. The analyst believes the company will likely appeal the loss, along with PTAB rulings rendered last week that other Copaxone patents were invalid. Gerberry sees the bull case scenario of Teva securing patent exclusivity of the Copaxone 40mg as unlikely and says a settlement with Momenta (MNTA) and Novartis (NVS) is the most logical course of action to mitigate 2017-2018E EPS risk. He reiterates an Outperform rating on Teva's shares.
09/20/16
CHDN
09/20/16
INITIATION
Target $95
CHDN
Buy
Novartis initiated with a Buy at Chardan
Chardan initiated Novartis with a Buy and a $95 price target.

TODAY'S FREE FLY STORIES

FRGI

Fiesta Restaurant

$25.95

-0.4 (-1.52%)

17:37
02/27/17
02/27
17:37
02/27/17
17:37
Hot Stocks
Fiesta Restaurant suspends sale evaluation process »

For the past four months,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

IPWR

Ideal Power

$2.40

-0.03 (-1.23%)

17:25
02/27/17
02/27
17:25
02/27/17
17:25
Earnings
Ideal Power reports Q4 EPS (29c), consensus (29c) »

Reports Q4 revenue $400K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

KRA

Kraton Performance

$27.49

0.68 (2.54%)

17:25
02/27/17
02/27
17:25
02/27/17
17:25
Earnings
Kraton Performance reports Q4 EPS 29c, consensus 33c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 07

    Mar

FLGT

Fulgent Genetics

$11.46

0.23 (2.05%)

17:19
02/27/17
02/27
17:19
02/27/17
17:19
Earnings
Fulgent Genetics reports Q4 EPS 6c, consensus 4c »

Reports Q4 revenue $5.9M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONB

Old National Bancorp

$18.65

-0.05 (-0.27%)

, FMER

FirstMerit

17:18
02/27/17
02/27
17:18
02/27/17
17:18
Hot Stocks
Old National names Michael Woods principal accounting officer »

Old National Bancorp…

ONB

Old National Bancorp

$18.65

-0.05 (-0.27%)

FMER

FirstMerit

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WNC

Wabash

$21.06

0.21 (1.01%)

17:17
02/27/17
02/27
17:17
02/27/17
17:17
Syndicate
Breaking Syndicate news story on Wabash »

Wabash files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTH

Anthera

$0.71

0.0142 (2.05%)

17:15
02/27/17
02/27
17:15
02/27/17
17:15
Earnings
Anthera reports Q4 EPS (36c), consensus (41c) »

The company ended the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$122.40

-0.33 (-0.27%)

17:13
02/27/17
02/27
17:13
02/27/17
17:13
Hot Stocks
Johnson & Johnson: DOJ inquires on Olysio, Massachusetts probes non-profit aid »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

ITGR

Integer

$36.95

0.55 (1.51%)

17:12
02/27/17
02/27
17:12
02/27/17
17:12
Hot Stocks
Integer announces Gary Haire joins company as CFO »

Integer Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

SHLM

A. Schulman

$33.75

0.05 (0.15%)

17:12
02/27/17
02/27
17:12
02/27/17
17:12
Hot Stocks
A. Schulman to open distribution center at Stryker, Ohio plant »

A. Schulman, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

SWX

Southwest Gas

$85.54

0.24 (0.28%)

17:10
02/27/17
02/27
17:10
02/27/17
17:10
Earnings
Southwest Gas reports Q4 EPS $1.37, consensus $1.35 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DERM

Dermira

$34.18

0.98 (2.95%)

17:09
02/27/17
02/27
17:09
02/27/17
17:09
Hot Stocks
Dermira to present data from DRM04, olumacostat glasaretil clinical programs »

Dermira announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

ALB

Albemarle

$92.46

-0.47 (-0.51%)

17:08
02/27/17
02/27
17:08
02/27/17
17:08
Earnings
Albemarle sees FY17 adjusted EPS $4.00-$4.25, consensus $4.07 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 16

    Mar

ALB

Albemarle

$92.46

-0.47 (-0.51%)

17:06
02/27/17
02/27
17:06
02/27/17
17:06
Earnings
Albemarle reports Q4 adjusted cont ops EPS 78c, consensus 73c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 16

    Mar

RAIL

FreightCar America

$14.60

-0.04 (-0.27%)

17:06
02/27/17
02/27
17:06
02/27/17
17:06
Earnings
FreightCar America reports Q4 EPS 1c, consensus 14c »

Reports Q4 revenue $…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

ZTO

ZTO Express

$14.57

0.42 (2.97%)

17:05
02/27/17
02/27
17:05
02/27/17
17:05
Earnings
ZTO Express sees Q1 revenue $360M-$374.4M, consensus $380.54M »

Representing a 27.6% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

ZTO

ZTO Express

$14.57

0.42 (2.97%)

17:03
02/27/17
02/27
17:03
02/27/17
17:03
Earnings
ZTO Express reports Q4 EPS 15c, consensus 16c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

WUBA

58.com

$32.49

0.52 (1.63%)

17:02
02/27/17
02/27
17:02
02/27/17
17:02
Earnings
Breaking Earnings news story on 58.com »

58.com sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

GLAD

Gladstone Capital

$9.22

0.1 (1.10%)

17:01
02/27/17
02/27
17:01
02/27/17
17:01
Hot Stocks
Gladstone Capital announces investment in unified communications business »

Gladstone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WUBA

58.com

$32.49

0.52 (1.63%)

17:01
02/27/17
02/27
17:01
02/27/17
17:01
Earnings
58.com reports Q4 adjusted EPS 0c, consensus (12c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

PRGO

Perrigo

$84.68

0.25 (0.30%)

16:57
02/27/17
02/27
16:57
02/27/17
16:57
Hot Stocks
Perrigo down 11% after results, FY17 guidance, CFO change »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 21

    Mar

STZ

Constellation Brands

$157.80

-1.05 (-0.66%)

16:56
02/27/17
02/27
16:56
02/27/17
16:56
Hot Stocks
Breaking Hot Stocks news story on Constellation Brands »

Soroban Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APPF

AppFolio

$25.05

1.25 (5.25%)

16:55
02/27/17
02/27
16:55
02/27/17
16:55
Earnings
Breaking Earnings news story on AppFolio »

AppFolio sees FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

RDN

Radian Group

16:55
02/27/17
02/27
16:55
02/27/17
16:55
Syndicate
Breaking Syndicate news story on Radian Group »

Radian Group files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APPF

AppFolio

$25.05

1.25 (5.25%)

16:54
02/27/17
02/27
16:54
02/27/17
16:54
Earnings
AppFolio reports Q4 EPS (4c), consensus (7c) »

Reports Q4 revenue $28M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.